Scott Wasserstrom, MD
Internal Medicine · Saint Louis, MONPI 1184679961
Payments from drug & device makers
Across 77 payments — averaging $18.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Jenavalve Technology, Inc.$171
- AstraZeneca$155
- AbbVie$117
- Pfizer$106
- Boehringer Ingelheim$82
- Novo Nordisk$81
- plus $695 from 15 others
What the payments were for
- Consulting fees$17112%
- Food & beverage$1,21386%
- Other$222%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Jenavalve Technology, Inc. | 1 | $171 |
| AstraZeneca | 12 | $155 |
| AbbVie(2 entities) | 6 | $117 |
| Pfizer | 7 | $106 |
| Boehringer Ingelheim | 6 | $82 |
| Novo Nordisk | 6 | $81 |
| Reprise Biomedical, Inc. | 1 | $80 |
| Amgen | 4 | $76 |
| Johnson & Johnson | 4 | $71 |
| Astellas Pharma US Inc | 3 | $68 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $65 |
| Novartis | 5 | $65 |
| Sanofi-aventis U.S. LLC | 3 | $52 |
| Lilly USA, LLC | 3 | $44 |
| GSK | 3 | $34 |
| Shire North American Group Inc | 2 | $32 |
| Arbor Pharmaceuticals, Inc. | 2 | $29 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $26 |
| Welch Allyn | 1 | $22 |
| Amarin Pharma, Inc. | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $13 |
How this compares
$1,407 in reported general payments places this provider in the 75th percentile of 2,097 internal medicine providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 120 | $138,718 |
| XareltoRivaroxaban | 39 | $57,649 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 46 | $49,598 |
| MounjaroTirzepatide | 23 | $23,156 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 88 | $23,020 |
| JardianceEmpagliflozin | 13 | $20,544 |
| OzempicSemaglutide | 14 | $15,375 |
| MyrbetriqMirabegron | 20 | $13,767 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 20 | $5,289 |
| Atorvastatin Calcium | 643 | $5,140 |
| Duloxetine Hcl | 130 | $4,850 |
| Rosuvastatin Calcium | 500 | $4,374 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 87 | $3,721 |
| Gabapentin | 176 | $3,338 |
| Levothyroxine Sodium | 329 | $3,190 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $106 | $138,718120 claims |
| GSKTrelegy Ellipta, Arexvy | $34 | $72,617134 claims |
| Johnson & JohnsonXarelto | $71 | $57,64939 claims |
| Lilly USA, LLCMounjaro | $44 | $23,15623 claims |
| Boehringer IngelheimJardiance | $82 | $20,54413 claims |
| Novo NordiskOzempic | $81 | $15,37514 claims |
| Astellas Pharma US IncMyrbetriq | $68 | $13,76720 claims |
| AbbVieSynthroid | $117 | $1,83324 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,097 internal medicine providers in Missouri.
Other internal medicine in Saint Louis
- Michael ReschakSaint Louis$3.1M
- David PrelutskySaint Louis$575K
- Danish JabbarSaint Louis$510K
- Hany SalamaSaint Louis$279K
- Lauren LevineSaint Louis$264K
- Brij VaidSaint Louis$213K
- Vinay KamatSaint Louis$191K
- Tracy NorfleetSaint Louis$132K
- Paul OlivoSaint Louis$98K
- Priyanka RavalSaint Louis$95K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.